[ET Net News Agency, 26 January 2021] Morgan Stanley lifted its target price for China
Medical System (CMS) (00867) to HK$14.3 from HK$12.5 and maintained its "overweight"
rating as its valuation looks attractive.
The research house raised its 2020 and outer-year forecasts to reflect the contributions
from health-related products, such as Plenity.
Morgan said CMS is the leading Chinese in-licensing entrant and has solid know-how in
drug in-licensing. It has six blockbuster drugs and seven in-licensed generics that could
hit the Chinese market during 2021-23.
CMS has a well-established sales network, leveraging on external R&D. The recovery looks
sustainable in view of the accelerating growth of key products and a more benign
centralized procurement policy. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00867 CMS
Nominal 
7.200 +0.130 (+1.839%) Research Report
26/01/2021 14:54
{I-bank focus}Morgan lifts CMS (00867) to HK$14.3
| Remark: | Real time quote last updated: 26/04/2024 16:37 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |